RxDoctor Payments Data

Hugo Davila, MD

Urology · Vero Beach, FLNPI 1063611598

Payments from drug & device makers

$54,144in general payments, 2019–2025

Across 464 payments — averaging $116.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BK Medical Holding Company Inc.$37K
  • Axonics, Inc.$5K
  • Boston Scientific$2K
  • Neotract Inc.$1K
  • Valencia Technologies Corporation$1K
  • Astellas Pharma US Inc$823
  • plus $6K from 54 others

What the payments were for

  • Consulting fees$7,84014%
  • Speaking & faculty fees$30,36956%
  • Travel & lodging$4,7539%
  • Food & beverage$10,72920%
  • Education$4531%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,144 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$733,223
Medicare patients
1,272
Services billed
9,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron78$71,100
GemtesaVibegron34$40,337
Tamsulosin Hcl713$12,195
Methenamine Hippurate34$4,892
Estradiol67$4,229
Silodosin24$3,183
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst196$2,317
Finasteride136$1,951
Cephalexin200$1,063
Fosfomycin Tromethamine12$819
Tadalafil18$774
Solifenacin Succinate16$525
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim168$493
Oxybutynin Chloride ErOxybutynin Chloride20$480
Dutasteride11$466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$823$71,10078 claims
Sumitomo Pharma America, Inc.Gemtesa$150$40,33734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.

Other urology in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →